SUMMARY Telenzepine is an analogue of pirenzepine with a higher potency and similar selectivity for MI-receptors in animals. In this placebo controlled, double blind, randomised study mean peptone stimulated gastric acid secretion (xZ±SEM) of 10 male healthy subjects (58±6 mmol H+/3 h for placebo) was significantly and dose dependently inhibited by oral telenzepine (2 mg: 31+5, 3 mg: 23±5, 5 mg: 21±4 mmol H+/3 h). Telenzepine 3 and 5 mg were significantly stronger than pirenzepine 50 mg orally (37±8 mmol H+/3 h). Mean percentage acid inhibition was 37% for pirenzepine, and 48, 61, and 64% for 2, 3, and 5 mg telenzepine, respectively. Basal and peptone stimulated gastrin release was unaffected. Mean salivary output per three hours declined moderately from 156±45 g (placebo) to 136±45 g with pirenzepine and significantly to 88±28 g, 95±39 g and 39±13 g with telenzepine 2, 3, and 5 mg, respectively. There was a parallel effect on Na+, K+, Ca++ and amylase output in saliva. Near point vision was not altered by either drug. Pulse rates were lowered by both substances. Complaints of dry mouth were more frequent with telenzepine 5 mg. On a molar basis telenzepine proved to be a 25 and 50 times more potent inhibitor of gastric and salivary secretion, respectively.
Telenzepine is a new analogue of pirenzepine having an altered tricyclic structure and an unchanged side chain (Fig. 1) . In animal studies, telenzepine was four to 10 times more potent than pirenzepine inhibiting gastric acid secretion.' It healed experimentally induced gastroduodenal ulcers more effectively and at lower doses than pirenzepine.2 Both compounds exhibited a similiar selectivity profile differing from that of atropine.' Therefore, telenzepine was considered to be a new MI-receptor antagonist, although receptor binding studies using telenzepine are lacking.
Pirenzepine has more selective inhibitory properties on oxyntic gastric glands and less antimuscarinic side effects than conventional antimuscarinics like atropine."4 In an oral dose of 100 to 150 mg daily pirenzepine proved to be superior to placebo and as effective as cimetidine in the treatment of patients with duodenal ulcer."4 Because of more pronounced antisecretory properties of telenzepine in animals' it was of interest to investigate its relationship of antimuscarinic effects and side effects in man. Therefore, we undertook this placebo controlled, double blind and randomised study in which the dose response of telenzepine 2, 3, and 5 mg orally was compared with the standard oral dose of pirenzepine 50 mg in 10 healthy male subjects. Peptone stimulated gastric acid secretion, gastrin release, spontaneous salivation, near point vision and peripheral pulse rates were synchronously measured. During each experiment the saliva of the subjects was collected by a standardised and continuous suction using a perfusor system (B Braun Melsungen AG, Melsungen/FRG, type 371 102) in a reverse direction. The saliva was aspirated through a small standardised tube (original perfusor tube no 872 296/0) positioned in the anterior oral cavity into a 50 ml syringe to avoid evaporation. The speed of suction was adapted to the individual flow rate; on average the speed was 30-60 ml per 30 minutes. The subjects were instructed neither to swallow nor to spit out saliva. Salivary output was measured in 30 minutes intervals by weighing. The concentrations of sodium and potassium were determined by flame photometry, calcium by colorimetric estimation using o-cresolphthalein complexone as indicator" and a-amylase by a direct spectrophotometric test using p-nitrophenyl a-maltoside as substrate.' Furthermore, accommodation was monitored by determining near point vision at definite intervals during the test; under standardised light conditions a Rodenstock accommodometer was used. We calculated the mean of the measurements of accommodation before medication in all five intraindividual comparisons; this was defined as zero point. The values after drug intake are given as difference from zero point. Peripheral pulse rates were recorded in a standardised manner.
Blood samples for determination of gastrin and drug concentrations were placed on ice. After clotting and centrifugation (at 4°C, 4000 g) the serum phase was separated and stored at -20°C. Serum gastrin concentrations were measured by a sensitive radioimmunoassay'3 using the specific antibody 4562 (kindly provided by Professor J F Rehfeld, Copenhagen, Denmark). Serum samples were analysed for concentrations of telenzepine using a gaschromatography-mass spectrometry assay, while pirenzepine was determined by radioimmunoassay. 4 88X9 could not detect any striking influence of either drug in the applied dosages. Peripheral pulse rates (Fig. 6) were lowered by either drug; the effects of 5 mg telenzepine and 50 mg pirenzepine were significant (p_0-01) at 90 minutes and at 125 and 185 minutes postdosing, respectively. intraindividual comparisons, with a mean coefficient of variation of about 10% in man.69' Second, it is a model for food stimulated gastric acid secretion and, contrary to pentagastrin test, allows simultaneous measurements of endogenous gastrin release. In this study, oral telenzepine had no influence on basal and peptone stimulated gastrin concentrations (Fig. 3) . This is in agreement with findings on basal serum gastrin published by Hacki et al. '5 In this respect, telenzepine shows the same behaviour as pirenzepine which does neither affect meal stimulated8 "'12 nor sham feeding induced gastrin release in man.22 Both differ from atropine which enhances significantly serum gastrin in man after food stimulation2324 and sham feeding.22 ' In agreement with our results, Hacki et all showed Both drugs reduced heart rate; the effect of pirenzepine was more pronounced (Fig. 6) . Significant reductions of heart rate have already been reported after parenteral'26 or high oral doses"7 of pirenzepine. Blurred vision as a symptom of impaired accommodation was only once noticed after pirenzepine, but not after telenzepine (Table 2) . Near point vision was not significantly altered by either drug (Fig. 5) Recent data' 1516 and our results with telenzepine have shown that structural alterations of the tricyclic structure of pirenzepine result in an increase of potency with regard to gastric acid inhibition in man. It would be interesting to study structure activity relationships of further pirenzepine analogues in order to develop even more potent and selective antimuscarinic drugs. In this connection, it should be mentioned that very recently another pirenzepine analogue with an altered side chain and an identical tricyclic structure (AF-DX 116) has been characterised by in vitro binding studies29 and by pharmacological studies in animals"' as a M2-receptor antagonist with cardioselective action.
In conclusion, telenzepine proved to be, on a molar basis, a 25 times more potent gastric antisecretagogue than pirenzepine under the conditions tested. Its closely related inhibition of salivation may limit the clinical application of higher doses of telenzepine as antiulcer drug. 
